Successful Progression to Second Cohort in AD04 Pharmacokinetics Study
Adial Pharmaceuticals (ADIL), a clinical-stage biopharmaceutical company dedicated to developing therapies for addiction and related disorders, has announced a significant milestone in its research efforts. The company has successfully progressed to the second cohort in the pharmacokinetics study of AD04, its lead investigational therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. The successful completion of the first cohort marks an important step in the development of this genetically targeted, serotonin-3 receptor antagonist.
Significant Milestone in AD04 Development
Cary Claiborne, President and Chief Executive Officer of Adial, expressed optimism about the progress of the pharmacokinetics study. “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial,” Claiborne stated.
Study Details and Objectives
Initiated in June 2024, the pharmacokinetics study of AD04 is a single-center, open-label relative bioavailability and dose proportionality study. It aims to enroll up to 30 healthy adult volunteers and will compare the pharmacokinetic profile of AD04 when administered as an oral dose of 0.33 mg with or without food against a reference standard product. This study will provide essential information on the pharmacokinetic properties of AD04, which are crucial for understanding how the drug is absorbed, distributed, metabolized, and excreted in the human body.
The primary objective of this study is to gather data that will inform the design of the Phase 3 Clinical Trial. By understanding the pharmacokinetic profile of AD04, Adial aims to optimize the dosing regimen and ensure the drug’s efficacy and safety for patients with AUD. This research is particularly important for heavy drinking patients, defined as those who consume fewer than 10 drinks per drinking day.
Future Directions and FDA Engagement
The anticipated completion of the pharmacokinetics study during the fourth quarter of 2024 will pave the way for the next steps in AD04’s development. Adial plans to engage with the FDA following the receipt of topline data from both cohorts. This interaction will be crucial for obtaining feedback on the overall design of the Phase 3 program, ensuring that the study meets regulatory requirements and addresses key endpoints necessary for potential approval.
Claiborne emphasized the importance of this collaboration with the FDA, stating, “We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.” This proactive approach underscores Adial’s commitment to developing effective and safe treatments for AUD, a condition that affects millions of individuals worldwide.
The Importance of AD04 in Treating AUD
Alcohol Use Disorder is a significant public health issue, with substantial social, economic, and health impacts. Current treatment options are limited and often ineffective for many patients, particularly those with heavy drinking patterns. AD04, as a genetically targeted therapeutic agent, offers a novel approach to treating AUD. By targeting specific serotonin receptors, AD04 aims to reduce the craving and consumption of alcohol, providing a potential new avenue for patients who have not responded to existing treatments.
The progression of AD04 through clinical trials represents a beacon of hope for individuals struggling with AUD. If successful, this therapy could significantly improve the quality of life for patients and reduce the burden of this disorder on healthcare systems.
Adial Pharmaceuticals’ advancement to the second cohort in the pharmacokinetics study of AD04 marks a critical milestone in the development of this promising treatment for Alcohol Use Disorder. The successful completion of this study will provide valuable insights necessary for the design of the upcoming Phase 3 Clinical Trial. As the company prepares to engage with the FDA and move forward with its development program, there is a growing sense of optimism about the potential impact of AD04 on the treatment landscape for AUD. Adial’s commitment to addressing addiction and related disorders underscores its dedication to improving patient outcomes and advancing public health.
Read original press release:here
You might like this article:Coca-Cola’s Strategic Moves Pay Off: A Surge in International Sales and Profit Forecasts
